Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zanubrutinib + rituximab + methotrexate + selinexor
- Development stage
- Phase 2
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is an investigational combination therapy being evaluated at Shanghai Ruijin Hospital for the treatment of newly diagnosed primary central nervous system lymphoma (PCNSL). The regimen consists of zanubrutinib, a second-generation Bruton tyrosine kinase (BTK) inhibitor; rituximab, an anti-CD20 monoclonal antibody; and high-dose methotrexate, a folate antagonist chemotherapy. In patients harboring TP53 mutations, the XPO1 inhibitor selinexor is added to the regimen. This biomarker-driven approach aims to improve outcomes in PCNSL, an aggressive B-cell lymphoma, by combining targeted therapy, immunotherapy, and traditional chemotherapy to enhance central nervous system penetration and overcome resistance mechanisms.
- Other names
- Zanubrutinib + Rituximab + MTX ± SelinexorZ(R)-MTX(TMZ) ± Selinexor
02
Targets
BTK (Bruton tyrosine kinase)CD20 (B-lymphocyte antigen CD20)DHFR (Dihydrofolate reductase)XPO1 (Exportin-1)
Beyond the preview
Go deeper on zanubrutinib + rituximab + methotrexate + selinexor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zanubrutinib + rituximab + methotrexate + selinexor.